Skip to main content
Log in

Hyperparathyroidism during growth hormone treatment: a role for puberty?

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract 

We describe three adolescent patients on chronic hemodialysis with a pubertal growth spurt who developed severe hyperparathyroidism during recombinant human growth hormone treatment. Parathyroid hormone levels were raised in parallel with the increase in linear growth in all patients. In two patients, hyperparathyroidism was successfully controlled with an increase in calcitriol dosage. In the third patient, growth hormone had to be withdrawn. We discuss the possibility that puberty is a risk factor for the development of hyperparathyroidism during growth hormone therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 2 September 1998 / Revised: 28 April 1999 / Accepted: 3 May 1999

Rights and permissions

Reprints and permissions

About this article

Cite this article

Picca, S., Cappa, M. & Rizzoni, G. Hyperparathyroidism during growth hormone treatment: a role for puberty?. Pediatr Nephrol 14, 56–58 (2000). https://doi.org/10.1007/s004670050014

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004670050014

Navigation